Valuation: Perspective Therapeutics, Inc.

Market Cap 341M 298M 275M 253M 478M 32.84B 488M 3.29B 1.29B 16.08B 1.28B 1.25B 55.37B P/E 2026 *
-2.71x
P/E 2027 * -2.64x
Enterprise Value 154M 134M 124M 114M 216M 14.82B 220M 1.48B 583M 7.26B 578M 565M 24.98B EV / Sales 2026 *
364x
EV / Sales 2027 * 58.9x
Free-Float
89.19%
Yield 2026 *
-
Yield 2027 * -
1 day+1.36%
1 week-0.66%
Current month-12.32%
1 month+1.36%
3 months-28.81%
6 months+28.33%
Current year+8.73%
1 week 2.82
Extreme 2.82
3.23
1 month 2.82
Extreme 2.82
3.78
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2023
Director of Finance/CFO 59 04/09/2025
Chief Tech/Sci/R&D Officer - 08/07/2026
Director TitleAgeSince
Director/Board Member 54 05/02/2023
Chairman 63 03/02/2023
Director/Board Member 60 05/02/2023
Date Insider Type Main position Quantity % Market Cap.
02/03/26 Free

Chief Technology Officer

150,000 0.1317%
02/03/26 Free

Director

50,000 0.0439%
02/03/26 Free

Chairman

50,000 0.0439%
Change 5-day change 1-year change 3-year change Capi.($)
+1.36%-0.66%-28.81%-51.38% 341M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.19%-0.04%+55.45%+81.79% 24.4B
Weighted average by Cap. -0.05%-0.18%+79.28%+123.05%

Financials

2026 *2027 *
Net sales 423K 370K 341K 315K 593K 40.75M 606K 4.08M 1.6M 19.96M 1.59M 1.55M 68.71M 488K 426K 393K 362K 683K 46.95M 698K 4.7M 1.85M 22.99M 1.83M 1.79M 79.16M
Net income -120M -105M -96.87M -89.29M -168M -11.57B -172M -1.16B -455M -5.67B -451M -441M -19.5B -138M -121M -111M -103M -194M -13.3B -198M -1.33B -524M -6.52B -519M -507M -22.43B
Net Debt -187M -164M -151M -139M -262M -18.02B -268M -1.8B -709M -8.83B -703M -687M -30.38B -312M -273M -252M -232M -438M -30.08B -447M -3.01B -1.18B -14.73B -1.17B -1.15B -50.71B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
17/07/26 $2.990 +1.36% 1,003,836
16/07/26 $2.950 -8.39% 1,479,409
15/07/26 $3.220 +5.57% 1,481,967
14/07/26 $3.050 -1.29% 2,810,123
13/07/26 $3.090 +2.66% 3,848,610
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.990USD
Average target price
12.93USD
Spread / Average Target
+332.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock